MyoPAXon
Phase 1Small molecule
MyoPAXon is one of 48 small molecule programs targeting Trial. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
139 competitors in Trial
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 3
Yervoy
Bristol-Myers SquibbPhase 3
Eloxatin
TevaPhase 3
Vectibix
AmgenPhase 3
Perjeta
RochePhase 3
Camptosar
PfizerPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Tarceva
OOSI Pharmaceuticals
Phase 3
Herceptin
OOrganon and Co
Phase 3
Adrucil
EElorac, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MyoPAXon. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details